...
首页> 外文期刊>Biochemical and Biophysical Research Communications >PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity
【24h】

PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity

机译:PPARalpha激动剂非诺贝特通过抑制氧化应激和MAPK活性来保护肾脏免受自发性高血压大鼠的高血压伤害

获取原文
获取原文并翻译 | 示例

摘要

Oxidative stress has been shown to play an important role in the development of hypertensive renal injury. Peroxisome proliferator-activated receptors a (PPARa) has antioxidant effect. In this study, we demonstrated that fenofibrate significantly reduced proteinuria, inflammatory cell recruitment and extracellular matrix (ECM) proteins deposition in the kidney of SHRs without apparent effect on blood pressure. To investigate the mechanisms involved, we found that fenofibrate treatment markedly reduced oxidative stress accompanied by reduced activity of renal NAD(P)H oxidase, increased activity of Cu/Zn SOD, and decreased phosphorylation of p38MAPK and JNK in the kidney of SHRs. Taken together, fenofibrate treatment can protect against hypertensive renal injury without affecting blood pressure by inhibiting inflammation and fibrosis via suppression of oxidative stress and MAPK activity.
机译:氧化应激已显示在高血压肾损伤的发展中起重要作用。过氧化物酶体增殖物激活受体α(PPARa)具有抗氧化作用。在这项研究中,我们证明了非诺贝特显着降低了SHR肾脏中的蛋白尿,炎性细胞募集和细胞外基质(ECM)蛋白沉积,而对血压没有明显影响。为了研究涉及的机制,我们发现非诺贝特治疗显着降低了氧化应激,并伴有肾脏NAD(P)H氧化酶活性降低,Cu / Zn SOD活性增强以及SHRs肾脏中p38MAPK和JNK磷酸化的降低。总之,非诺贝特治疗可通过抑制氧化应激和MAPK活性来抑制炎症和纤维化,从而在不影响血压的情况下保护高血压肾脏免受损害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号